登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，5月19日，Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-20

  • Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

    Matthew J Cummings, MD

    Matthew R Baldwin, MD

    Darryl Abrams, MD

    Samuel D Jacobson, BA

    Benjamin J Meyer, BA

    Elizabeth M Balough, MPhil

    Published:May 19, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31189-2

    Summary

    Background

    Over 40?000 patients with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed.

    Methods

    This prospective observational cohort study took place at two NewYork-Presbyterian hospitals affiliated with Columbia University Irving Medical Center in northern Manhattan. We prospectively identified adult patients (aged ≥18 years) admitted to both hospitals from March 2 to April 1, 2020, who were diagnosed with laboratory-confirmed COVID-19 and were critically ill with acute hypoxaemic respiratory failure, and collected clinical, biomarker, and treatment data. The primary outcome was the rate of in-hospital death. Secondary outcomes included frequency and duration of invasive mechanical ventilation, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clinical deterioration following admission. The relation between clinical risk factors, biomarkers, and in-hospital mortality was modelled using Cox proportional hazards regression. Follow-up time was right-censored on April 28, 2020 so that each patient had at least 28 days of observation.

  • 原文来源：https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31189-2/fulltext
33浏览量
原文链接
相关报告

  • 《Lancet，5月28日，Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-29
    • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M Kuderer, MD † Toni K Choueiri, MD † Dimpy P Shah, PhD † Yu Shyr, PhD † Samuel M Rubinstein, MD Donna R Rivera, PharmD et al. Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31187-9 Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.
    139浏览量
    原文链接

  • 《LANCET，5月28日，COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-29
    • COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lennard Y W Lee, DPhil * Prof Jean Baptiste Cazier, PhD * T Starkey, MSc C D Turnbull, DPhil UK Coronavirus Cancer Monitoring Project Team Rachel Kerr, FRCP † et al. Show all authors Show footnotes Published:May 28, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31173-9 Summary Background Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer. Methods In this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission.
    98浏览量
    原文链接